Cargando…

Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model

BACKGROUND: Mounting evidence shows that multi-intervention programmes for hypertension treatment are more effective than an isolated pharmacological strategy. Full economic evaluations of hypertension management programmes are scarce and contain methodological limitations. The aim of the study was...

Descripción completa

Detalles Bibliográficos
Autores principales: Perman, Gastón, Rossi, Emiliano, Waisman, Gabriel D, Agüero, Cristina, González, Claudio D, Pallordet, Carlos L, Figar, Silvana, Gonz&#225lez Bernaldo de Quirós, Fernán, Canning, JoAnn, Soriano, Enrique R
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084155/
https://www.ncbi.nlm.nih.gov/pubmed/21466695
http://dx.doi.org/10.1186/1478-7547-9-4
_version_ 1782202459098185728
author Perman, Gastón
Rossi, Emiliano
Waisman, Gabriel D
Agüero, Cristina
González, Claudio D
Pallordet, Carlos L
Figar, Silvana
Gonz&#225lez Bernaldo de Quirós, Fernán
Canning, JoAnn
Soriano, Enrique R
author_facet Perman, Gastón
Rossi, Emiliano
Waisman, Gabriel D
Agüero, Cristina
González, Claudio D
Pallordet, Carlos L
Figar, Silvana
Gonz&#225lez Bernaldo de Quirós, Fernán
Canning, JoAnn
Soriano, Enrique R
author_sort Perman, Gastón
collection PubMed
description BACKGROUND: Mounting evidence shows that multi-intervention programmes for hypertension treatment are more effective than an isolated pharmacological strategy. Full economic evaluations of hypertension management programmes are scarce and contain methodological limitations. The aim of the study was to evaluate if a hypertension management programme for elderly patients is cost-effective compared to usual care from the perspective of a third-party payer. METHODS: We built a cost-effectiveness model using published evidence of effectiveness of a comprehensive hypertension programme vs. usual care for patients 65 years or older at a community hospital in Buenos Aires, Argentina. We explored incremental cost-effectiveness between groups. The model used a life-time framework adopting a third-party payer's perspective. Incremental cost-effectiveness ratio (ICER) was calculated in International Dollars per life-year gained. We performed a probabilistic sensitivity analysis (PSA) to explore variable uncertainty. RESULTS: The ICER for the base-case of the "Hypertension Programme" versus the "Usual care" approach was 1,124 International Dollars per life-year gained. PSA did not significantly influence results. The programme had a probability of 43% of being dominant (more effective and less costly) and, overall, 95% chance of being cost-effective. DISCUSSION: Results showed that "Hypertension Programme" had high probabilities of being cost-effective under a wide range of scenarios. This is the first sound cost-effectiveness study to assess a comprehensive hypertension programme versus usual care. This study measures hard outcomes and explores robustness through a probabilistic sensitivity analysis. CONCLUSIONS: The comprehensive hypertension programme had high probabilities of being cost-effective versus usual care. This study supports the idea that similar programmes could be the preferred strategy in countries and within health care systems where hypertension treatment for elderly patients is a standard practice.
format Text
id pubmed-3084155
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-30841552011-04-29 Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model Perman, Gastón Rossi, Emiliano Waisman, Gabriel D Agüero, Cristina González, Claudio D Pallordet, Carlos L Figar, Silvana Gonz&#225lez Bernaldo de Quirós, Fernán Canning, JoAnn Soriano, Enrique R Cost Eff Resour Alloc Research BACKGROUND: Mounting evidence shows that multi-intervention programmes for hypertension treatment are more effective than an isolated pharmacological strategy. Full economic evaluations of hypertension management programmes are scarce and contain methodological limitations. The aim of the study was to evaluate if a hypertension management programme for elderly patients is cost-effective compared to usual care from the perspective of a third-party payer. METHODS: We built a cost-effectiveness model using published evidence of effectiveness of a comprehensive hypertension programme vs. usual care for patients 65 years or older at a community hospital in Buenos Aires, Argentina. We explored incremental cost-effectiveness between groups. The model used a life-time framework adopting a third-party payer's perspective. Incremental cost-effectiveness ratio (ICER) was calculated in International Dollars per life-year gained. We performed a probabilistic sensitivity analysis (PSA) to explore variable uncertainty. RESULTS: The ICER for the base-case of the "Hypertension Programme" versus the "Usual care" approach was 1,124 International Dollars per life-year gained. PSA did not significantly influence results. The programme had a probability of 43% of being dominant (more effective and less costly) and, overall, 95% chance of being cost-effective. DISCUSSION: Results showed that "Hypertension Programme" had high probabilities of being cost-effective under a wide range of scenarios. This is the first sound cost-effectiveness study to assess a comprehensive hypertension programme versus usual care. This study measures hard outcomes and explores robustness through a probabilistic sensitivity analysis. CONCLUSIONS: The comprehensive hypertension programme had high probabilities of being cost-effective versus usual care. This study supports the idea that similar programmes could be the preferred strategy in countries and within health care systems where hypertension treatment for elderly patients is a standard practice. BioMed Central 2011-04-05 /pmc/articles/PMC3084155/ /pubmed/21466695 http://dx.doi.org/10.1186/1478-7547-9-4 Text en Copyright ©2011 Perman et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Perman, Gastón
Rossi, Emiliano
Waisman, Gabriel D
Agüero, Cristina
González, Claudio D
Pallordet, Carlos L
Figar, Silvana
Gonz&#225lez Bernaldo de Quirós, Fernán
Canning, JoAnn
Soriano, Enrique R
Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model
title Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model
title_full Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model
title_fullStr Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model
title_full_unstemmed Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model
title_short Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model
title_sort cost-effectiveness of a hypertension management programme in an elderly population: a markov model
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084155/
https://www.ncbi.nlm.nih.gov/pubmed/21466695
http://dx.doi.org/10.1186/1478-7547-9-4
work_keys_str_mv AT permangaston costeffectivenessofahypertensionmanagementprogrammeinanelderlypopulationamarkovmodel
AT rossiemiliano costeffectivenessofahypertensionmanagementprogrammeinanelderlypopulationamarkovmodel
AT waismangabrield costeffectivenessofahypertensionmanagementprogrammeinanelderlypopulationamarkovmodel
AT aguerocristina costeffectivenessofahypertensionmanagementprogrammeinanelderlypopulationamarkovmodel
AT gonzalezclaudiod costeffectivenessofahypertensionmanagementprogrammeinanelderlypopulationamarkovmodel
AT pallordetcarlosl costeffectivenessofahypertensionmanagementprogrammeinanelderlypopulationamarkovmodel
AT figarsilvana costeffectivenessofahypertensionmanagementprogrammeinanelderlypopulationamarkovmodel
AT gonz225lezbernaldodequirosfernan costeffectivenessofahypertensionmanagementprogrammeinanelderlypopulationamarkovmodel
AT canningjoann costeffectivenessofahypertensionmanagementprogrammeinanelderlypopulationamarkovmodel
AT sorianoenriquer costeffectivenessofahypertensionmanagementprogrammeinanelderlypopulationamarkovmodel